Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Safety, Tolerability, Pharmacokinetics, and Quantitative EEG Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures

Trial Profile

A Phase 2a, Safety, Tolerability, Pharmacokinetics, and Quantitative EEG Study of CX-8998 in Adolescents and Adults With Idiopathic Generalized Epilepsy With Absence Seizures

Recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2018

At a glance

  • Drugs CX 8998 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Proof of concept
  • Acronyms T-WAVE
  • Sponsors Cavion
  • Most Recent Events

    • 19 Nov 2018 Planned End Date changed from 25 Nov 2018 to 25 Mar 2019.
    • 19 Nov 2018 Planned primary completion date changed from 25 Nov 2018 to 25 Jan 2019.
    • 26 Jul 2018 Parallel assignment has been changed to single group assignment. Now study is open labelled, previously it was double blind. Treatment arms and planned patient number has been reduced.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top